Company Description
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy.
It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane.
In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics.
Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E.
coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer.
Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma.
CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
| Country | Germany |
| Founded | 2000 |
| IPO Date | Aug 14, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 983 |
| CEO | Alexander Zehnder |
Contact Details
Address: Friedrich-Miescher-Strasse 15 Tübingen, 72076 Germany | |
| Phone | 49 7071 9883 0 |
| Website | curevac.com |
Stock Details
| Ticker Symbol | CVAC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $16.00 |
| CIK Code | 0001809122 |
| CUSIP Number | N2451R105 |
| ISIN Number | NL0015436031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | Chief Executive Officer, MD and Member of Management Board |
| Axel-Sven Malkomes | Chief Financial Officer and Member of Executive Board |
| Dr. Malte Greune Ph.D. | Chief Operating Officer, Member of Management Board and MD |
| Dr. Myriam Mendila M.D. | Chief Scientific Officer, Head of Research & Development, MD and Member of the Management Board |
| Thaminda Ramanayake | Chief Business Officer and Member of Executive Board |
| Dr. Sarah Fakih | Vice President Corporate Communications and Investor Relations |
| Marco Rau L.L.M., Ph.D. | General Counsel |
| Slavica Stevanovic-Heck | Head of Human Resources |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior Vice President and Area Head of Oncology |
| Dr. Patrick Baumhof | Senior Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Apr 7, 2025 | 6-K | Report of foreign issuer |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Jan 7, 2025 | 144 | Filing |
| Jan 7, 2025 | 144 | Filing |
| Jan 7, 2025 | 144 | Filing |
| Jan 7, 2025 | 144 | Filing |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |